Two new genes involved in the more aggressive prostate cancer

May 13, 2014, IDIBELL-Bellvitge Biomedical Research Institute
This is researcher Alvaro Aytes. Credit: Toni Soriano (ICO)

A study by the Columbia University Nova York, in collaboration with the Catalan Institute of Oncology , Belvitge Biomedical Research Institute (ICO-IDIBELL) has identified two new genes that lead to more aggressive forms of prostate cancer. The work done by Alvaro Aytes under the direction of Cory Abate-Shen , director of the Herbert Irving Comprehensive Cancer Center of the Columbia University, has been published in the latest issue of Cancer Cell.

Prostate cancer

Prostate cancer is the most common in men in Europe( accounts for 20% of all male tumors). The incidence is about 60 new cases per 100,000 inhabitants per year.

A tumor closely associated with old age, and most cases is diagnosed between 70 and 80 years. The progressive aging of the population has made it one of the tumors that has increased in recent decades. Survival is quite high: according to Oncology Master Plan, 84 % of patients are alive five years after diagnosis.

Identify high-risk patients

In a significant proportion of patients the has a not very aggressive behavior, which does not compromise the health and quality of life of the affected. Also, being a tumor that usually occurs in old age, often the person dies with the tumor but not as a result of this.

It is therefore necessary to develop tools to predict which prostate tumors are clinically relevant and potentially lethal. This would open the door to customize treatments and avoid certain therapies and , therefore, avoid side effects to patients that do not need it, further reducing healthcare costs.

Two new genes in the spotlight

The study published in Cancer Cell identified two genes, the FOXM1 and CENPF, if they are abnormally activated simultaneously, lead to more aggressive and life threatening forms of prostate cancer .

A new feature of the study is that computer algorithms were used to generate networks of interactions between molecules that are generated specifically in .

Currently they have launched preclinical studies to determine which treatments or combinations of drugs are more effective in combating abnormal activation of FOXM1 and CENPF genes. Also, in the near future, identifying the presence or absence of these biomarkers in an individual patient will provide a more effective and with fewer side effects individualized treatment.

Explore further: Two genes together drive aggressive prostate cancer

Related Stories

Two genes together drive aggressive prostate cancer

May 12, 2014
Two genes work together to drive the most lethal forms of prostate cancer, according to new research from the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC). These findings could lead ...

Low testosterone levels may indicate worsening of disease for men with prostate cancer

May 5, 2014
For men with low-risk prostate cancer, low levels of testosterone may indicate a worsening of their disease. That's the conclusion of a new study published in BJU International. The findings may help physicians identify patients ...

Older, sicker men with early-stage prostate cancer do not benefit from aggressive treatment

May 13, 2014
Treating older men with early-stage prostate cancer who also have other serious underlying health problems with aggressive therapies such as surgery or radiation therapy does not help them live longer and, in fact, can be ...

Vitamin D deficiency linked to aggressive prostate cancer

May 1, 2014
African-American and European-American men at high risk of prostate cancer have greater odds of being diagnosed with an aggressive form of the disease if they have a vitamin D deficiency, according to a new study from Northwestern ...

Researchers identify genetic variants predicting aggressive prostate cancers

June 19, 2013
Researchers at Moffitt Cancer Center and colleagues at Louisiana State University have developed a method for identifying aggressive prostate cancers that require immediate therapy. It relies on understanding the genetic ...

Novel study charts aggressive prostate cancer

November 18, 2013
Many patients diagnosed with prostate cancer have indolent, slow-growing forms of the disease that are not life-threatening. However, more than 30,000 American men will die from aggressive prostate cancer this year alone. ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.